Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$76.7 million.

  • ImmunityBio's Net Cash Flow fell 32284.42% to -$76.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.0 million, marking a year-over-year increase of 2266.12%. This contributed to the annual value of -$121.9 million for FY2024, which is 17563.09% down from last year.
  • ImmunityBio's Net Cash Flow amounted to -$76.7 million in Q3 2025, which was down 32284.42% from $76.9 million recorded in Q2 2025.
  • ImmunityBio's Net Cash Flow's 5-year high stood at $134.5 million during Q3 2023, with a 5-year trough of -$144.5 million in Q1 2022.
  • Its 5-year average for Net Cash Flow is $1.4 million, with a median of $319000.0 in 2022.
  • Per our database at Business Quant, ImmunityBio's Net Cash Flow tumbled by 156400.28% in 2022 and then surged by 2733479.62% in 2023.
  • Over the past 5 years, ImmunityBio's Net Cash Flow (Quarter) stood at $116.5 million in 2021, then tumbled by 99.73% to $319000.0 in 2022, then surged by 27334.8% to $87.5 million in 2023, then tumbled by 63.87% to $31.6 million in 2024, then plummeted by 342.71% to -$76.7 million in 2025.
  • Its Net Cash Flow stands at -$76.7 million for Q3 2025, versus $76.9 million for Q2 2025 and -$82.8 million for Q1 2025.